Detalhe da pesquisa
1.
A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614).
Pediatr Blood Cancer
; 71(6): e30938, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38520670
2.
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.
Pediatr Blood Cancer
; 71(3): e30817, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38189770
3.
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
Cancer
; 129(14): 2245-2255, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37081608
4.
Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics.
Pediatr Blood Cancer
; 70 Suppl 6: e30563, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37430453
5.
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
Pediatr Blood Cancer
; 70(12): e30672, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37710306
6.
Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Pediatr Blood Cancer
; 70(6): e30293, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36916768
7.
Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1).
Pediatr Blood Cancer
; 70(11): e30609, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37553297
8.
Congenital Infantile Fibrosarcoma Involving Pelvic Wall and Thigh Soft Tissues and Placenta, Presenting with Coagulopathy.
Pediatr Dev Pathol
; 25(6): 656-660, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35834223
9.
Development of an exosomal gene signature to detect residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning.
Lab Invest
; 101(12): 1585-1596, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34489559
10.
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Pediatr Blood Cancer
; 68(9): e29065, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33881209
11.
A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
Pediatr Blood Cancer
; 68(4): e28892, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33438318
12.
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Lancet Oncol
; 21(4): 541-550, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32192573
13.
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.
Cancer
; 126(24): 5303-5310, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32914879
14.
Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.
Pediatr Blood Cancer
; 67(10): e28636, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32762028
15.
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Pediatr Blood Cancer
; 67(2): e28073, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724813
16.
The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Cancer
; 125(2): 290-297, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30351457
17.
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Lancet Oncol
; 19(9): 1229-1238, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30122620
18.
A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).
Cancer
; 124(23): 4548-4555, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30394521
19.
Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).
Pediatr Blood Cancer
; 65(5): e26944, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29292843
20.
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Pediatr Blood Cancer
; 65(8): e27066, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29719113